Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11452714
Antibacterial agents including histidine kinase inhibitors
granted -
US 11452709
Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
granted -
US 11446365
Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
granted -
US 11447508
Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
granted -
US 11447452
Agonists of peroxisome proliferator-activated receptor alpha and methods of use
granted -
US 11446302
Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
granted -
US 11446253
Ionic liquids for internal delivery
granted -
US 11447753
Non-neuroinvasive viruses and uses thereof
granted -
US 11446279
Aromatic 2-nitrosulfonyl fluoride antibiotics and methods of use thereof
granted -
US 11446353
Compositions and methods for the treatment of fungal infections
granted -
US 11447563
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
granted -
US 11447830
Gene signatures to predict drug response in cancer
granted -
US 11439650
Thermo-kinetic mixing for pharmaceutical applications
granted -
US 11439615
Lipoxin and lipoxin analogue mediated neuroprotection and treatments
granted -
US 11439656
Pharmaceutical compounds and uses thereof
granted -
US 11439611
Administration of serine protease inhibitors to the stomach
granted -
US 11439659
Methods and compositions to prevent and treat inflammation and allergic reactions
granted -
US 11439725
Bioresorbable embolization microspheres
granted -
US 11439708
Nanotube trans-membrane channels mimicking biological porins
granted -
US 11439609
Nitric oxide releasing PLGA microspheres for biomedical applications
granted -
US 11439695
Kidney injury treatment
granted -
US 11440885
Substituted 1-arylalkyl-4-acylaminopiperidine compounds and methods of producing and using the same
granted -
US 11433118
Long-acting VEGF inhibitors for intraocular neovascularization
granted -
US 11433038
High concentration medicant solutions for treating neurological disorders
granted -
US 11432547
Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same
granted -
US 11434267
Peptides having reduced toxicity that stimulate cholesterol efflux
granted -
US 11433013
Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use thereof
granted -
US 11433088
Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
granted -
US 11433126
Protection from stress, anxiety, neuroinflammation, and cognitive dysfunction
granted -
US 11435366
Noninvasive method to quantify kidney function and functional decline
granted -
US 11434233
Heterocyclic inhibitors of ATR kinase
granted -
US 11434301
Anti-CD46 antibodies and methods of use
granted -
US 11433143
Nano-enabled immunotherapy in cancer
granted -
US 11433091
Methods and compositions for administration of iron
granted -
US 11435349
CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
granted -
US 11426366
Compositions and methods for treating motor disorders
granted -
US 11426448
Methods for treatment of erectile dysfunction with sonic hedgehog compounds
granted -
US 11426368
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
granted -
US 11427588
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
granted -
US 11426464
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
granted -
US 11427816
Cancer treatment through RLIP76 partial depletion
granted -
US 11426409
Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
granted -
US 11426420
Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
granted -
US 11421010
T cells expressing membrane-anchored IL-12 for the treatment of cancer
granted -
US 11419888
Composition and method for promoting reduction of heat stress in animals
granted -
US 11422132
Peptides and uses thereof for diagnosing and treating myasthenia gravis
granted -
US 11419883
Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
granted -
US 11413278
Compounds and methods for promoting stress resistance
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory